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Synopsis
Turner syndrome is one of the most common chromosomal abnormalities affecting female infants. 
The severity of clinical manifestations generally varies and affects multiple organ systems. 
Women with Turner syndrome have a threefold increase in mortality, which becomes even more 
pronounced in pregnancy. There are several reproductive options available for women with Turner 
syndrome, including adoption or surrogacy, assisted reproductive techniques, and in rare cases 
spontaneous pregnancy. There are well-documented risks for women with Turner syndrome 
during pregnancy, including specific risks of aortic pathology, hepatic disease, thyroid disease, 
type 2 diabetes, and Cesarean section delivery. Several professional societies have published 
guidelines to aid in the care of women with Turner syndrome prior to and during pregnancy. It is 
important for providers who care for these women to be familiar with the specific risks and 
recommendations in caring for women with Turner syndrome of reproductive age.
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Introduction
Turner syndrome, defined as typical features in a phenotypic female with partial or complete 
loss of the second sex chromosome, is one of the most common chromosomal abnormalities, 
with an annual incidence of 1:2500 live born female infants (1), (2). Approximately 50% of 
affected women are missing an entire X chromosome and have a karyotype of 45,X. About 
25% have a partial deletion of one X chromosome, while about 20% have varying degrees 
of mosaicism, most commonly a 45,X/46,XX karyotype (3). A small group of affected 
women carries an XY cell line.
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In general, the phenotypic severity of Turner syndrome varies with the extent of X 
chromosome loss. Clinical manifestations of Turner syndrome (FIGURE 1) may be 
categorized as abnormalities affecting multiple organ systems, including the skeletal, 
cardiovascular and lymphatic, endocrine, gastrointestinal, renal, and the central nervous 
system (TABLE 1). Major morbidities may occur during adult life, and these result in a 
threefold increase in mortality (4). Particularly relevant to the discussion of reproductive 
function is the increased prevalence of aortic root dilatation and aortic dissection, which 
occur in 32% and 1-2% of affected women, respectively (5), (6). Dissection occurs at an 
average age of 31.5 years, making it particularly relevant to women in their reproductive 
years (7).
Ovarian Development in Females with Turner Syndrome
In the normal developing human, the number of non-growing ovarian follicles increases 
through the first half of gestation, reaching an average maximum of 300,000 per ovary at 
18-22 weeks of gestation (8). Oogonia enter meiosis, which is arrested at prophase I, 
forming oocytes. Oocytes are incorporated into primordial follicles starting at 14-20 weeks 
of gestation. Throughout the second half of gestation, the number of non-growing follicles 
remains fairly constant, and by birth the number of follicles averages 295,000 per ovary. 
This number then decreases over pre-pubertal life, reaching about 180,000 per ovary by the 
age at menarche, and then declines further in an accelerating fashion until menopause 
(FIGURE 2).
During the first trimester, ovarian development in fetuses with Turner syndrome is initially 
normal. Examination of ovaries at 14 to 18 weeks gestation has revealed normal gonadal 
development (9). Shortly thereafter, however, oocyte loss is accelerated in many girls with 
Turner syndrome, with oocyte depletion being nearly complete prenatally or by the first few 
months after birth. In fetuses with 46,XX karyotypes, oogonia were seen as early as 18 
weeks, ovaries from 20 weeks onward were found to have primordial follicles, and preantral 
and antral follicles were seen at 26 weeks. In contrast, some ovaries from fetuses with 45,X 
karyotypes had oogonia, but no follicles were visualized (10). There is evidence that some 
girls with Turner syndrome continue to have oocytes and functional follicles after birth. In a 
study to assess for the presence of ovarian follicles in adolescents with Turner syndrome, ¼ 
to 1 ovary was removed laparoscopically from nine adolescent girls with Turner syndrome 
and histologically analyzed. Eight of the nine ovaries had follicles, with higher numbers of 
follicles in younger adolescents and girls with mosaicism. Follicular density inversely 
correlated with FSH level (11).
Pubertal maturation in Turner syndrome
Gonadotropins and ovarian hormone production
In 46,XX fetal development, the hypothalamic-pituitary-gonadal axis becomes active in late 
gestation. At birth, there is a surge of luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) (9). In newborns with Turner syndrome, an exaggerated FSH surge has been 
documented, suggesting the onset of ovarian failure. Elevated FSH levels during infancy 
decline between the ages of 4-11 years as they do in normal girls, although average FSH 
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concentrations in children with Turner syndrome are generally higher than normal (9). After 
the age of 11 years, FSH concentrations in girls with Turner syndrome again rise sharply to 
levels much higher than those typically seen in normal puberty (12) . Using an ultrasensitive 
assay, pre-pubertal girls with Turner syndrome were found to have lower estradiol levels 
when compared with age-matched girls without Turner syndrome.
Chromosomal analysis was performed on a group of 40 patients diagnosed with Turner 
syndrome with variable degrees of mosaicism. Six of these patients had spontaneous 
menarche, with the remainder having primary amenorrhea. Cytogenetic analyses showed 
that in those with mosaicism, the presence of at least 10% euploid cells is predictive of 
spontaneous pubertal development (13).
Ovarian and uterine growth
Uterine development is altered in girls with Turner syndrome. A cohort of 38 patients with 
Turner syndrome was followed longitudinally, and serial pelvic ultrasounds were performed 
to document ovarian and uterine size before and during the expected time of puberty. 
Twenty-seven to forty-six percent of patients had ultrasonographically detectable ovaries; in 
these patients, the authors documented an initial increase in ovarian size at a skeletal age of 
approximately nine years, and this increase became more pronounced after 14 years of age, 
suggesting continued estrogen production in these patients. Seventy-six percent of the 
patients with mosaic Turner syndrome had two detectable ovaries and larger ovarian 
volumes, compared to girls with 45,X karyotypes, of whom only 26% had ovaries detected 
by ultrasonography. Girls with mosaicism more frequently had spontaneous thelarche (50%) 
and menarche (38.5%) than those with 45,X karyotypes. Uterine size was only assessed in 
patients who were not prescribed estrogen therapy, and increased in all patients with Turner 
syndrome; however, girls with mosaicism had larger increases in uterine size than girls with 
45,X karyotypes. Even though all Turner syndrome patients had increased uterine size, these 
measurements were still significantly lower than those from the control group (14).
Menstrual function
Menarche is infrequent in girls with Turner syndrome. However, one recent report noted that 
as many as 40-50% of girls with Turner syndrome may have some observed pubertal 
development. Rates are higher in girls with mosaic karyotypes, but up to 25% of girls with 
45,X karyotypes have some signs of spontaneous puberty. Up to 10% of girls with Turner 
syndrome achieve menarche (15). In another study, 522 subjects with Turner syndrome were 
observed for spontaneous puberty, and spontaneous menarche occurred in 84 (16.1%) 
subjects (16). During follow up, 30 patients were found to have regular menses nine years 
after the onset of menarche, 12 patients developed secondary amenorrhea 1-3 years after the 
onset of menarche, and 19 patients developed oligomenorrhea. Of the remaining patients, 
long-term data were not available in ten, and 13 were lost to follow up. Spontaneous 
menarche was more common in patients with mosaicism than in those with 45,X karyotypes, 
leading the investigators to conclude that the additional X chromosome likely has a 
significant influence on the progression of puberty. Additionally, a serum FSH level less 
than 10 mIU/mL at age 12 years is predictive of the onset of spontaneous menarche and 
regular cycles (17).
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As the majority of patients with Turner syndrome (>80%) do not undergo spontaneous 
puberty or menarche, estrogen therapy is typically required to initiate pubertal development 
(16). The age at which estrogen is initiated varies but is generally around age 12 years. 
Estrogen is initiated in very low doses, generally 1/10 to 1/8 the adult dose, and slowly 
increased to full replacement doses over a period of two years to promote normal breast and 
uterine growth. After two years of treatment or once breakthrough bleeding occurs, a 
progestin is typically added to allow for regular menstrual cycles. With the assistance of 
hormone therapy, girls with Turner syndrome may have regular monthly menses throughout 
life until hormone therapy is discontinued at the typical time of menopause (2).
Pregnancy in Turner syndrome
Spontaneous pregnancy can be seen in a small percentage of individuals with Turner 
syndrome and generally is more likely in women with mosaicism and those who report 
spontaneous puberty and regular menses (18,19). There are, however, reports of individuals 
with 45,X karyotypes spontaneously conceiving and delivering healthy infants, indicating 
that although women with mosaicism are more likely to conceive spontaneously, women 
with monosomy may also be fertile. Over 90% of women with Turner syndrome who have 
spontaneous pregnancies have a mosaic karyotype (18-21). In a study of 482 women with 
Turner syndrome, 57 women (12%) reported a total number of 124 pregnancies, occurring 
either spontaneously or through IVF. Twenty-seven women (47%) became pregnant using 
their own oocytes – of these, 23 women (85%) conceived spontaneously, and four (15%) 
with the use of either in vitro fertilization or insemination. Thirty women (53%) became 
pregnant as a result of oocyte donation. Ninety-two percent of the women who achieved 
pregnancy via autologous oocyte transfer were found to have a mosaic karyotype (19).
Assisted reproductive technology
In rare incidences, individuals with Turner syndrome are able to conceive spontaneously and 
deliver. For the vast majority of women with Turner syndrome, however, infertility is 
inevitable. In the past, all women with Turner syndrome were advised to avoid pregnancy 
entirely due to risks of complications. However, recent studies have shown that in selected 
cases women with Turner syndrome are able to become pregnant successfully and deliver 
healthy infants. There are several options for women with Turner syndrome who desire to 
have children: adoption and surrogate gestational carriers have been the two most 
traditionally recommended options, although more recently additional alternatives have been 
developed that allow women with Turner syndrome to carry and deliver children 
themselves.
The most commonly sought fertility option is in vitro fertilization (IVF) with donor oocytes 
(22). In this option, a donor oocyte is obtained and fertilized, with the resulting embryo 
being transferred into the uterus of the individual with Turner syndrome – donor IVF. 
Oocyte donation programs cite pregnancy success rates of 24-47%, which are consistent 
with pregnancy rates in women undergoing IVF who do not have Turner syndrome (23). 
Khastgir et al. cite an implantation rate of 17.1% per embryo transferred at a facility in 
London (24). Miscarriages are most often due to the presence of a hypoplastic or bicornuate 
uterus and a thinner endometrial lining than that typically seen in pregnant women without 
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Turner syndrome (24). Due to the comparatively small uterine size of women with Turner 
syndrome, even after hormonal preparation to ensure adequate uterine growth, is it 
recommended that only one embryo be transferred per IVF cycle to prevent undue 
complications, many of which will be discussed later in this review. Hormone replacement 
therapy is continued during the IVF process for up to 12 weeks, until the placenta is able to 
produce sufficient amounts of estrogens and progestins to maintain the pregnancy (25).
More recently, there have been reports of women with Turner syndrome who have 
functional ovaries undergoing IVF using their own oocytes – autologous IVF. In this option 
if a woman with Turner syndrome is thought to be a good candidate, she undergoes FSH-
stimulation to promote follicle growth. Her own individual follicles are then removed and 
cryopreserved, later undergoing in vitro fertilization and implantation. Predictors for 
successful autologous IVF include a mosaic peripheral blood karyotype, normal serum FSH 
and AMH levels, and spontaneous puberty. Negative predictors for successful autologous 
IVF are monosomy or a structurally anomalous X chromosome, elevated FSH levels, low 
AMH levels, and lack of spontaneous puberty (22), (15), (26).
Timing for oocyte retrieval is controversial. Although some girls do have spontaneous 
puberty, the vast majority does not, and those who start puberty spontaneously often do not 
complete puberty or have premature ovarian failure in the teenage years. It may be better to 
obtain oocytes for cryopreservation before ovarian failure begins. Additionally, there have 
been several case reports of adolescents and adults with Turner syndrome undergoing 
ovarian stimulation followed by both oocyte and ovarian tissue cryopreservation for later 
IVF (27), (28), (29). However, there is currently no evidence regarding the safety of ovarian 
stimulation regimens in pre-pubertal females, and it is unknown what effect these treatments 
may have on overall pubertal development or adult height. An alternative is laparoscopic 
ovarian wedge resection with subsequent cryopreservation. This approach has succeeded in 
a 16 year old girl with mosaic Turner syndrome (30).
Pregnancy outcomes
Pregnancy outcomes in women with Turner syndrome have been studied closely. In 2011 
Bryman et al. reported an overall delivery rate of live babies in 54%, with a rate of 44% in 
pregnancies that resulted from autologous oocytes, either spontaneous pregnancies or with 
IVF assistance, and a rate of 74% in pregnancies resulting from oocyte donation (19). In the 
68 live births, only 5 infants (7.4%) were found to have complications or birth defects, 
including cerebral palsy, neuropsychological disorder, coarctation of the aorta, cleft lip and 
palate, and congenital tumor. The infants were non-dysmorphic and without chromosomal 
anomalies. Tarani et al. cited a 20% rate of birth defects in children born to women with 
Turner syndrome, and a higher incidence of chromosomal abnormalities, including trisomy 
21 (31). In a Belgian study, 24 women with Turner syndrome were followed from 
conception to delivery. Pregnancies were monitored for complications in both mothers and 
infants, and the authors documented a miscarriage rate of 23%. However, when considering 
loss of biochemical pregnancies as well, the rate of early pregnancy losses approached 44% 
(32). A recent study of 103 women with Turner syndrome who underwent oocyte donation 
with IVF reported reassuring neonatal outcomes with life-birth per embryo transfer rates 
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ranging from 30.5-33.3%, preterm birth rate of 8%, low birth weight in 8.8%, and major 
birth defects in 3.8%, with overall perinatal mortality of 2.3%. These numbers are reassuring 
due to their similarity to neonatal complication rates in normal pregnancies (6).
Risks and complications of pregnancy
Cardiovascular disorders
Despite improved expectations for fertility in individuals with Turner syndrome, pregnancy-
related mortality remains higher than in the general population, approximately 2% compared 
to 0.013% in normal women (33). One of the most significant risks is worsening of 
cardiovascular disease during pregnancy. Coarctation of the aorta and bicuspid aortic valve 
are the two most common cardiovascular manifestations in Turner syndrome, with 
prevalence rates of 11% and 16%, respectively (2). Other cardiovascular abnormalities 
include elongated transverse aortic arch, partial anomalous pulmonary connection, and 
persistent left superior vena cava (34). In addition, women with Turner syndrome also have 
dilated vasculature when compared to those with 46,XX karyotypes, particularly dilatation 
of the aortic root (2). Women with Turner syndrome are at increased risk for aortic 
dissection or rupture related to the increased cardiovascular stress that occurs during 
pregnancy. Another reason that single oocyte transfer is recommended for women 
undergoing IVF (see above) is that the stress on the cardiovascular system increases with 
multiple gestations. There is also some evidence that the changes to the aorta persist even 
after pregnancy and can be exacerbated by subsequent pregnancies (35). Due to these risks, 
it is imperative to perform careful pre-conception counseling and screening in all women 
with Turner syndrome who are considering pregnancy. Specific factors that increase the risk 
of aortic dissection or rupture during pregnancy include aortic size index (ASI) of >2.0 
cm/m2, history of surgery to repair cardiovascular defects, bicuspid aortic valve, current 
aortic dilatation, and systemic hypertension (2,36). Despite careful screening and intra-
pregnancy monitoring, aortic dissection and rupture can still occur, and the risk for this is 
highest in the third trimester of pregnancy or postpartum (37). Women with any of these risk 
factors should be offered alternatives to pregnancy, including adoption and surrogacy.
Hypertension and its sequelae, including pre-eclampsia and eclampsia, are major risks for 
cardiovascular complications during pregnancy. Pregnancy-induced hypertension is defined 
as two elevated blood pressure readings ≥140/90 mm Hg occurring after 20 weeks of 
gestation, measured at least 4 hours apart or on two separate occasions, and pre-eclampsia is 
defined as elevated blood pressure in combination with proteinuria. The incidence of any 
pregnancy-associated hypertensive disorder in women with Turner syndrome is variable and 
has been reported to range from 35% to 67% (6,38). Severe hypertensive syndromes such as 
pre-eclampsia, eclampsia, and HELLP syndrome (hemolysis, elevated liver enzymes, and 
low platelets) have been documented in 50% of women with Turner syndrome and 
hypertension during pregnancy. In a study of 21 women with Turner syndrome, Bodri et al. 
documented pregnancy-associated hypertensive disorders in 5 patients – two with 
pregnancy-induced hypertension, two with pre-eclampsia, and one with HELLP syndrome 
(38). One hypothesis for the increased incidence of pre-eclampsia is endothelial dysfunction 
resulting from a mismatch between pro-angiogenic factors, such as vascular endothelial 
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growth factor, and anti-angiogenic factors including soluble fms-like tyrosine kinase 1 (39). 
There is some thought that the higher incidence of intra-uterine growth restriction and pre-
term births seen in the infants of women with Turner syndrome could be related to 
pregnancy-associated hypertension. Therefore, careful blood pressure screening both before 
and during pregnancy is indicated.
Hepatic disease
Non-pregnant women with Turner syndrome are more likely to have abnormal liver function 
tests, including elevated concentrations of transaminases and alkaline phosphatase, as well 
as an increased incidence of regenerative nodular hyperplasia and portal hypertension (2). In 
1998, a review of the Danish Cytogenetic Central Register revealed a relative risk of 5.69 
for cirrhosis in women with Turner syndrome compared to the general population (40). A 
more recent study of 218 women with Turner syndrome in Sweden noted elevated 
concentrations of liver enzymes in 36% of patients at baseline, with an additional 23% 
developing abnormalities at the five year follow up evaluation (41). Six percent of the 
original cohort of women normalized their transaminase levels at follow up. Six of the 
women with abnormal liver enzyme concentrations underwent liver biopsy, and pathology 
was consistent with cholangitis and hepatitis C in one subject each, with steatosis and 
normal biopsies in two patients each.
With an increased incidence at baseline, there is concern that pregnancy may contribute to 
worsening liver disease. A retrospective cohort study of 106 European women with Turner 
syndrome revealed that two women (1.9%) had elevated liver enzyme concentrations at 
baseline (6). During pregnancy, six women were found to have intrahepatic cholestasis, and 
one woman developed HELLP syndrome requiring early Cesarean-section delivery. 
Although it is clear that hepatic disease is more common in women with Turner syndrome 
than in the general population, further studies are required before the magnitude of risk 
during pregnancy can be determined.
Thyroid disease
Thyroid dysfunction is common in women with Turner syndrome, with a prevalence 
approaching 24%. However, the incidence of hypothyroidism appears to increase during 
pregnancy (2), with reported rates ranging from 7.7%-43.8%, (6,42). Comparatively, in 
normal women the incidence of thyroid dysfunction in pregnancy is around 1-2% (43). To 
prevent complications from uncontrolled or undiagnosed maternal hypothyroidism, all 
women with Turner syndrome should have annual thyroid function testing, including TSH, 
either total or free thyroxine, and anti-thyroid antibodies (6).
Diabetes and glucose metabolism
It is well known that women with Turner syndrome are at a higher risk of glucose 
intolerance and diabetes when compared to normal women (2). In one study of 26 adult 
women with Turner syndrome who underwent oral glucose tolerance testing, 38.4% had 
abnormal glucose tolerance, and 7.7% were diagnosed with type 2 diabetes (44). In a study 
of 57 pregnancies in Swedish women with Turner syndrome with previously normal glucose 
tolerance, 5% were found to have gestational diabetes (19). One hundred ten women with 
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Turner syndrome who became pregnant via oocyte donation were followed for nearly 20 
years, and 9.4% of pregnancies were complicated by gestational diabetes (6). The increased 
incidence of diabetes in women with Turner syndrome is thought to be related to impaired 
first-phase insulin secretion caused by pancreatic beta cell dysfunction, and this effect 
appears to be amplified during sex hormone administration. Gravholt et al. reported 26 
women with Turner syndrome who underwent oral glucose tolerance testing prior to and 
after receiving six months of sex hormone replacement therapy (40). A majority of the 
women had impaired first-phase insulin secretion at baseline as well as lower basal insulin 
levels; these effects were intensified after six months of sex hormone therapy. Because 
pregnancy is a condition in which sex hormone levels are significantly elevated, pregnant 
women with Turner syndrome are more likely to develop diabetes. Hence, these women 
should be screened diligently prior to and during pregnancy to ensure gestational diabetes is 
promptly diagnosed.
Cesarean section delivery
Due to their short stature and narrow pelvic diameter, women with Turner syndrome have a 
higher rate of Cesarean section (C-section) deliveries than normal women (2). Bryman et al. 
evaluated 124 pregnancies in 57 Swedish women with Turner syndrome and documented C-
section rates of 63% in women who became pregnant using their own oocytes and 80% after 
oocyte donation, compared to a C-section rate of 16% in the general population (19). 
Hagman et al. evaluated 117 pregnancies in 106 women with Turner syndrome. They found 
that C-sections, either planned or emergent, were performed in 82% of all deliveries; 34.4% 
of these were emergent. The most common reasons for non-emergent C-sections were 
cephalo-pelvic disproportion and breech presentation. Induction of labor was attempted in 
34% of the women. However, 72.2% of these attempts required unplanned C-section due to 
slow labor or failure to progress. Only 21% of women were able to deliver via spontaneous 
vaginal delivery. (6). Risks of C-section delivery include pelvic fetal head impaction, 
hemorrhage, uterine atony, damage to bladder or bowel, and complications from anesthesia 
(45). As women with Turner syndrome have a significantly higher rate of C-section delivery 
than those without Turner syndrome, the risks of C-section delivery should be discussed 
thoroughly during pre-pregnancy counseling.
Pre-pregnancy counseling
Due to the pregnancy risks specific to women with Turner syndrome, all women of 
reproductive age who have been diagnosed with Turner syndrome should be provided with 
comprehensive pre-pregnancy counseling. Although uncommon, women with Turner 
syndrome have been reported to spontaneously conceive. Therefore, all women should be 
provided with adequate information regarding the importance of contraception (18,20). The 
risks of increased overall mortality, cardiovascular disease (including aortic dissection, 
hypertension, pre-eclampsia and eclampsia), liver disease, hypothyroidism, diabetes, and the 
increased chance of Cesarean delivery should all be discussed as part of the pre-pregnancy 
visit. Due to the risks of pregnancy, all women with Turner syndrome should be informed of 
alternative methods to expand their families, including adoption or surrogacy. These options 
should be especially stressed in women who have relative contraindications for pregnancy 
(2).
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Professional society recommendations
Several professional organizations and expert groups have developed consensus guidelines 
and position statements regarding pregnancy in women with Turner syndrome, with 
relatively similar recommendations, (36), (46), (2), (TABLE 2) and many other authors 
have put forward additional suggestions (22), (33), (47). All women carrying the diagnosis 
of Turner syndrome are at risk during pregnancy, and there is no distinction between those 
with 45,X karyotypes and those with partial X chromosome deletions or mosaic karyotypes. 
A careful, complete pre-pregnancy medical evaluation is mandated, including meticulous 
cardiovascular assessment with cardiac imaging using echocardiography and cardiac MRI. 
Consultation with specialists in cardiovascular disease, endocrinology, and high-risk 
obstetrics is required to ensure the best chance for a successful pregnancy and delivery of a 
healthy infant. Pregnancy is considered contraindicated in the presence of significant 
hypertension or structural cardiac disease, including bicuspid aortic valve, aortic coarctation, 
and aortic dilatation at baseline. Mothers require detailed pre-pregnancy counseling about 
the increased risk for aortic dilatation and aortic dissection and the increased risk for C-
section. If assisted reproductive technology is required, a single embryo should be 
transferred to avoid the increased risks of multiple gestation. Throughout pregnancy, close 
follow up with subspecialty care is needed, including periodic echocardiography or MRI, 
and monitoring of thyroid dysfunction, glucose metabolism, hepatic function, and blood 
pressure. At delivery, if there is no evidence of aortic dilatation, vaginal delivery may be 
attempted. However, if the aortic size index or absolute aortic diameter is increased, the 
infant should be delivered by C-section, without allowing the mother to labor.
Conclusions
Turner syndrome is one of the most common chromosomal abnormalities, with clinical 
manifestations affecting multiple organ systems. As children with Turner syndrome 
transition into adulthood it is important for practitioners to be familiar with screening 
guidelines and health concerns, particularly in regards to fertility and pregnancy. There are 
unique health issues to consider in women with Turner syndrome who desire fertility, 
including stature, cardiovascular risk, and disorders of the endocrine system, including 
thyroid disease and type 2 diabetes. It is imperative that providers who care for women with 
Turner syndrome be familiar with the current guidelines in order to provide the highest level 
of care.
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Key Points
• Turner syndrome is one of the most common chromosomal abnormalities in 
female infants.
• Clinical manifestations of Turner syndrome include abnormalities of the 
following organ systems: skeletal, cardiovascular and lymphatic, endocrine, 
gastrointestinal, renal, and the central nervous system.
• Ovarian function sufficient to result in puberty is uncommon, and subsequent 
fertility is even less common in women with Turner syndrome. However, there 
are several options for women who desire to expand their families.
• Due to the unique pregnancy risks and complications in women with Turner 
syndrome it is important to be familiar with the current guidelines for pre-
conception counseling and monitoring during gestation.
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Figure 1. 
Adolescent with Turner syndrome. Note the phenotypic features, including ptosis, down 
slanting palpebral fissures, micrognathia, low set and posteriorly rotated ears, low posterior 
hairline, and pigmented nevi. Figure courtesy of Erica Eugster, M.D.
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Figure 2. 
Changes in ovarian follicle number across the life span in normal subjects. These data were 
derived from eight histological studies of ovaries from subjects ranging from seven weeks 
post-conception to 51 years. Note the rapid proliferation up to 18-22 weeks post-conception 
and the gradually increasing rate of decline until menopause. Figure courtesy of Wallace and 
Kelsey, 2010. (8) NGF, Non-growing follicles; PI, Prediction interval
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Table 1
Phenotypic features of Turner syndrome
Skeletal system
Short stature
Broad chest
Scoliosis
Cubitus valgum
Short 4th metacarpal
Madelung deformity of the wrist
Genu valgum
Cardiovascular and Lymphatic systems
Bicuspid aortic valve
Coarctation of the aorta
Hypertension
Aortic root dilatation
Aortic dissection
Lymphedema of hands and feet
Pterygium colli
Low posterior hairline
Low-set and posteriorly rotated ears
Down slanting palpebral fissures
Endocrine system
Primary ovarian failure
Hashimoto thyroiditis
Glucose intolerance
Type 2 diabetes mellitus
Gastrointestinal system
Celiac disease
Central nervous system
Sensorineural hearing loss
Attention deficit-hyperactivity disorder
Learning disability
Decreased visuospatial skills and executive function
Renal system
Duplicated renal collecting system
Horseshoe kidney
Other
Arched palate
Micrognathia
Otitis media
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Conductive hearing loss
Pigmented nevi
Hyperconvex fingernails
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